First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Go back to First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.86 +0.65 (6.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.21 | 52 Week High | $2.18 | |||
| Open | $10.81 | 52 Week Low | $0.30 | |||
| Day High | $11.07 | P/E | N/A | |||
| Day Low | $10.74 | EPS | $-3.32 | |||
| Volume | 157,614 | |||||
